GLP1_Psoriasis_SupplementaryTable1

Published: 15 August 2025| Version 1 | DOI: 10.17632/w33cctb9cp.1
Contributors:
Amanda Paredes-Barbeito, Madison Downs

Description

Supplemental table 1 summarizes the characteristics and outcomes of the studies included in our review including study design, sample size, study duration, dosages, etc.

Files

Categories

Psoriasis, Glucagon-Like Peptide-1 Receptor Agonist

Licence